Quantcast

North Bay Business Journal

Monday, April 19, 2010, 1:28 pm

BioMarin launches drug in Europe

By

Print Friendly Print Friendly    

Share this item

    NOVATO — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Firdapse is now commercially available in Germany and the UK.

    For the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome, Firdapse is expected to be in all major European markets by the end of 2010. The drug received marketing approval in the E.U. in December 2009 and is the first approved treatment for this condition, thereby conferring orphan drug protection and providing ten years of market exclusivity in Europe.

    “The launch of Firdapse brings the first specifically approved treatment option for LEMS to patients in the E.U. and marks our fourth commercial product on the market,” said Jean-Jacques Bienaime, chief executive officer of BioMarin. “We look forward to meeting with the FDA in the second quarter of 2010 to determine the necessary regulatory path for Firdapse in the U.S.”

    BioMarin, which develops enzyme therapies for rare diseases, employs 700 in Novato.

    Copyright © 1988–2014 North Bay Business Journal
    View the policy for linking to website content.

    Print Friendly Print Friendly    

    Submit Your Comments

    Required

    Required, will not be published

    Comments are moderated and generally will be posted if they are on-topic and not abusive. For more information, please see our Comments and Letters Policy. To share this item by email or social media, use the links above.

    Do not use this form to contact people, companies or organizations mentioned in this story. Contact them directly. Private messages left here will be deleted.